Centrophenoxine for Health & Longevity

Evidence Review created on 08/03/2026 using AI4L / Opus 4.8

Also known as: Meclofenoxate, Meclofenoxate Hydrochloride, Lucidril, Helfergin, Cerutil, ANP 235

Motivation

Centrophenoxine (also known as meclofenoxate) is a synthetic compound created in the late 1950s to support memory and mental function. It joins two smaller molecules: a choline-like substance made naturally in small amounts in the brain, and a plant-derived carrier that helps that substance reach brain tissue more easily. It has long attracted interest because animal studies suggest it can clear a waste pigment that builds up inside cells as they age.

For decades it was prescribed in parts of Europe, Japan, and China for age-related memory loss, poor blood flow to the brain, and states of confusion in older people. In the United States it was never approved as a medicine and is instead sold, often unofficially, as a memory supplement. Its most talked-about laboratory finding is that treated animals seem to accumulate less of the age-related waste pigment in their brain cells than untreated animals.

This review examines what is actually known about centrophenoxine for health and longevity: how it is thought to work, the strength of the evidence behind its claimed benefits, the risks and practical considerations of using it, and where the science remains uncertain.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Meclofenoxate - Grokipedia

Grokipedia’s dedicated article, filed under the pharmacological name meclofenoxate, provides a broad reference overview of the compound’s chemistry, history, pharmacology, and uses.

Examine

Centrophenoxine - Examine

Examine’s evidence-based supplement page frames centrophenoxine as a better-absorbed carrier of DMAE, summarizes its dosing and its use for reducing age-related waste-pigment buildup, and offers a cautious read of the cognition evidence.

ConsumerLab

ConsumerLab has no stand-alone product review, test, or dedicated page for centrophenoxine. The compound is only referenced within its broader memory-and-cognition supplement answer and in a 2022 ConsumerLab clinical update (“Less Centrophenoxine in Supplements Than Stated”) reporting that most US products tested contained less than the labeled amount — a sourcing and dosing concern reflected in the Sourcing and Quality section of this review.

Systematic Reviews

The following systematic reviews evaluate centrophenoxine (meclofenoxate) among cholinergic agents; both are meta-analyses (a statistical method that pools results from multiple trials) rather than reviews dedicated to the compound alone.

Cholinergic medication for antipsychotic-induced tardive dyskinesia - Tammenmaa-Aho et al., 2018

This Cochrane review pooled randomized controlled trials (RCTs — studies that randomly assign participants to treatment or placebo) of cholinergic drugs, including meclofenoxate, for tardive dyskinesia (a movement disorder of repetitive, involuntary movements). It found the evidence too small and low-quality to show benefit, illustrating how thin the controlled human data are for this compound.
Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials - Tammenmaa et al., 2004

An earlier meta-analysis of eleven RCTs (261 patients) that specifically named meclofenoxate and found no statistically significant benefit for the older cholinergic agents (relative risk 0.84 — relative risk is the ratio of an outcome’s likelihood between the treatment and control groups; 95% confidence interval 0.68–1.04 — the confidence interval is the range within which the true value most likely lies). It is a useful direct check on the limits of the human trial base.

Note: Fewer than five items are listed because no systematic review or meta-analysis dedicated specifically to centrophenoxine for cognition or longevity exists on PubMed as of 08/03/2026; the two above are the only systematic reviews that formally evaluate the compound.

Mechanism of Action

Centrophenoxine is an ester (a chemical join) of two parts: DMAE (dimethylaminoethanol, a molecule closely related to choline) and pCPA (para-chlorophenoxyacetic acid, a synthetic plant-growth-type carrier). After it is taken, esterases (enzymes that split ester bonds) in the blood and liver rapidly break it back into these two components.

Its proposed actions are:

Cholinergic support: The DMAE component is thought to raise availability of choline and thereby of acetylcholine (a signaling chemical the brain uses for memory and attention). This is the “cholinergic” (acetylcholine-related) mechanism shared with related nootropics.
Antioxidant / free-radical scavenging: Centrophenoxine can neutralize the hydroxyl radical (one of the most damaging reactive oxygen molecules) and, in animals, lowers markers of fat-membrane oxidation such as MDA (malondialdehyde, a byproduct of lipid damage) while supporting scavenging enzymes such as SOD (superoxide dismutase, an antioxidant enzyme).
Lipofuscin clearance: In animal brains it reduces accumulation of lipofuscin, the fatty “age pigment” that builds up inside long-lived cells such as neurons.
Membrane / cellular-water effects: The compound’s leading academic proponent, Imre Zs-Nagy, proposed the “membrane hypothesis of aging,” in which centrophenoxine restores the electrical and water properties of the cell membrane in aged cells.

Competing interpretations exist. Proponents (notably Zs-Nagy) argue the membrane and antioxidant effects translate into a genuine slowing of aging, while skeptics hold that the human cognitive evidence is weak and that the striking findings are largely confined to animal models; both positions are represented in the literature.

Key pharmacological properties. Half-life: the parent ester is short-lived because it is hydrolyzed within minutes in plasma, so effects depend on the released DMAE (which itself clears over hours). Selectivity: non-selective; it acts broadly through cholinergic and antioxidant pathways rather than a single receptor. Tissue distribution: it crosses the blood-brain barrier (the protective filter around the brain) and concentrates in brain and liver. Metabolism: primarily esterase-mediated hydrolysis to DMAE and pCPA rather than the liver’s CYP (cytochrome P450, the main drug-metabolizing enzyme family, e.g. CYP3A4) system; DMAE is then further metabolized and partly excreted in urine.

Historical Context & Evolution

Original intended use: Centrophenoxine was synthesized in 1959 by researchers associated with the French National Centre for Scientific Research and marketed as Lucidril. Its first medical uses were for cerebrovascular disorders (poor brain blood flow), age-related cognitive decline, confusional states, and recovery after stroke or head injury.
Why it came to be considered for health optimization: From the 1970s onward, gerontology researchers—most prominently Imre Zs-Nagy in Hungary and Kalidas Nandy in the United States—reported that the compound reduced lipofuscin and improved learning in aged animals. These findings reframed it from a symptomatic brain medicine into a candidate longevity agent, and it was later adopted by the longevity and nootropic communities.
What the historical research actually found: Early animal work (Nandy, 1978; and later replications) documented reduced neuronal age pigment and improved maze performance in old mice, while small mid-20th-century clinical studies in older patients with memory impairment reported mixed, generally modest cognitive changes.
How the science evolved—without treating the current view as final: As rigorous trial standards emerged, the two systematic reviews of cholinergic agents that included meclofenoxate found no clear benefit for tardive dyskinesia, and no large modern longevity trial has been run. This has shifted mainstream opinion toward skepticism. That shift reflects an absence of high-quality confirmatory trials rather than direct disproof of the animal findings, and newer work (e.g., killifish transcriptome and Parkinson’s-related laboratory studies) continues to probe the original observations from both supportive and cautionary directions.

Expected Benefits

Benefits are grouped by the strength of the underlying evidence and framed for risk-aware adults seeking to optimize long-term brain health.

Medium 🟩 🟩

Reduction of Neuronal Lipofuscin (Age Pigment)

The most consistent finding across independent animal laboratories is that centrophenoxine reduces the accumulation of lipofuscin, the fatty waste pigment that builds up inside neurons with age and is considered a hallmark of cellular aging. The proposed mechanism combines antioxidant activity with enhanced cellular clearance. The evidence basis is multiple animal studies (mice, guinea pigs, rats) using microscopy and autofluorescence, including the classic Nandy work; direct human brain data are lacking, which caps the grade at Medium.

Magnitude: Rodent and guinea-pig studies report roughly 20–50% reductions in neuronal lipofuscin over about 8–12 weeks of treatment.

Low 🟩

Small and mostly older clinical studies in elderly patients with memory impairment or early dementia reported improvements in memory, alertness, and concentration, and animal studies show faster learning. However, the two systematic reviews that formally evaluated meclofenoxate found no statistically significant benefit, and trial quality is generally poor, so the human signal is genuinely conflicted. The benefit, if real, appears limited to those with existing age-related decline rather than healthy young users.

Magnitude: Reported effects are modest and inconsistent—small improvements on memory and clinical-status scales in some trials, no significant effect in pooled analyses.

Antioxidant and Membrane Protection

In aged animals, centrophenoxine lowers markers of oxidative damage (such as MDA) and supports antioxidant enzymes, and it is proposed to restore membrane properties in aged cells. This provides a plausible cellular rationale for its longevity claims. The evidence basis is animal biochemistry (e.g., aged-rat studies combining it with ginkgo or zinc); human confirmation is absent.

Magnitude: Not quantified in available studies.

Neuroprotection in Cerebral Hypoperfusion

In a rat model of chronic reduced brain blood flow, oral centrophenoxine improved spatial memory and reduced neuronal degeneration, normalizing oxidative and inflammatory markers. This supports its historical use in cerebrovascular cognitive impairment. The evidence basis is a controlled animal study (Liao et al., 2004); it has not been confirmed in adequately powered human trials.

Magnitude: In the cited rat study, treatment (100 mg/kg/day for 37 days) markedly improved water-maze performance and attenuated neuronal damage versus untreated animals.

Speculative 🟨

Lifespan Extension

Centrophenoxine is frequently promoted as a life-extension agent based on isolated mid-20th-century reports that it increased the average survival of aged laboratory rodents. These findings have not been reliably replicated, no human longevity data exist, and the basis remains largely mechanistic (antioxidant and age-pigment effects) and anecdotal.

Neurodegenerative Disease Modification

Laboratory work suggests centrophenoxine can inhibit aggregation of alpha-synuclein (the protein that clumps in Parkinson’s disease) and raise dopamine in animal models, hinting at possible disease-modifying potential. This is based only on in-vitro and animal experiments, with no clinical evidence.

Benefit-Modifying Factors

Genetic polymorphisms: No well-characterized pharmacogenetic markers govern centrophenoxine response. Because its effect is largely cholinergic, variants affecting choline metabolism or acetylcholine signaling could theoretically influence responsiveness, but this is unstudied.
Baseline biomarker levels: Individuals with higher baseline oxidative stress or age-related cognitive decline appear most likely to show measurable benefit; those already optimized are less likely to notice change.
Sex-based differences: Direct human data are lacking, but at least one animal transcriptome study found the brain-gene response to meclofenoxate was more pronounced in females, suggesting possible sex-related differences worth noting.
Pre-existing health conditions: Benefit is most plausible in people with age-related cognitive impairment or reduced cerebral blood flow, and least relevant in healthy younger adults.
Age-related considerations: The animal and clinical benefit signals are concentrated in aged subjects; older adults at the upper end of the target range are the group in whom benefits (lipofuscin clearance, cognitive support) are most likely to be meaningful.

Potential Risks & Side Effects

Risks are grouped by evidence strength. Because no large modern safety trials exist, no risk reaches the High tier; most data come from the DMAE-cholinergic drug class and clinical experience.

Medium 🟥 🟥

Overstimulation and Insomnia

The cholinergic and mildly stimulating action can cause restlessness, agitation, and difficulty sleeping, especially at higher doses or when taken late in the day. This is the most frequently reported reason users lower the dose or stop. The evidence basis is clinical use and the well-documented profile of DMAE-class compounds; it is generally reversible on dose reduction.

Magnitude: Commonly reported at daily doses in the upper range (roughly 1,000 mg and above) and largely avoidable by dosing earlier in the day.

Headache

Headache is among the most commonly reported effects, often attributed to increased cholinergic activity outpacing available choline. It is typically mild and reversible. The evidence basis is user reports and the cholinergic class profile; adding a choline source is a frequently described mitigation.

Magnitude: Not quantified in available studies.

Low 🟥

Gastrointestinal Upset

Nausea, stomach discomfort, and reduced appetite can occur, particularly when taken on an empty stomach. The evidence basis is anecdotal and clinical experience; it is usually mild and reversible by taking the compound with food.

Magnitude: Not quantified in available studies.

Cholinergic Symptoms

Excess acetylcholine activity can produce jaw or muscle tension, increased salivation, and, rarely, muscle twitching. The evidence basis is the pharmacology of cholinergic agents and scattered reports; symptoms resolve with dose reduction.

Magnitude: Not quantified in available studies.

Irritability, Agitation, and Blood Pressure Effects

At higher doses some users report irritability, agitation, or a sense of overstimulation, and cholinergic and stimulant-like activity could affect blood pressure. The evidence basis is clinical observation and class effects; those with anxiety, agitation, or uncontrolled hypertension appear most susceptible.

Magnitude: Not quantified in available studies.

Speculative 🟨

Reproductive and Developmental Risk

The DMAE component has been linked to developmental abnormalities in some animal studies, so use during pregnancy or breastfeeding is considered inadvisable. This concern is based on animal and mechanistic data for DMAE rather than direct centrophenoxine trials.

Long-Term Safety and pCPA Exposure Uncertainty

Because the compound releases a chlorinated phenoxyacetate fragment and has never undergone long-term human safety study, chronic high-dose use carries unquantified uncertainty. In addition, a US analysis found supplement products frequently mislabeled the amount present, compounding real-world exposure uncertainty. The basis is regulatory and analytical reports rather than documented harm.

Risk-Modifying Factors

Genetic polymorphisms: No validated genetic markers predict adverse response. Variants influencing acetylcholinesterase activity or choline handling could in theory alter sensitivity to cholinergic side effects, but this is unstudied.
Baseline biomarker levels: People with baseline high blood pressure or a tendency to anxiety/agitation may be more prone to overstimulation-type effects.
Sex-based differences: No reliable human data establish sex-based differences in side effects; the animal evidence of a stronger female brain-gene response is of unknown clinical relevance to risk.
Pre-existing health conditions: Those with seizure disorders, uncontrolled hypertension, severe agitation, or bipolar disorder are theoretically at higher risk of cholinergic or stimulatory adverse effects; pregnancy and breastfeeding are relative contraindications due to the DMAE component.
Age-related considerations: Older adults may be more sensitive to both cholinergic effects and blood-pressure changes and often take interacting medications, warranting lower starting doses at the upper end of the target age range.

Key Interactions & Contraindications

Other cholinergics and choline sources (supplements): Combining with DMAE, alpha-GPC, citicoline, or choline can be additive and helpful for reducing headache, but stacking too many raises the chance of cholinergic excess. Severity: caution; consequence: headache, jaw tension, agitation. Mitigating action: introduce one at a time and adjust total choline load.
Acetylcholinesterase inhibitors (prescription drugs — donepezil, rivastigmine, galantamine, and the supplement huperzine A): These raise acetylcholine and can be additive with centrophenoxine. Severity: caution to avoid; consequence: cholinergic excess (nausea, salivation, muscle effects). Mitigating action: avoid concurrent use or use only under medical supervision.
Racetam nootropics (supplements — piracetam, aniracetam): Commonly stacked; can increase cholinergic demand and headache. Severity: caution; consequence: headache. Mitigating action: ensure adequate choline intake and separate dose adjustments.
Anticholinergic medications (over-the-counter and prescription — diphenhydramine, oxybutynin, tricyclic antidepressants): These oppose centrophenoxine’s mechanism and may blunt its effect. Severity: monitor; consequence: reduced efficacy or unpredictable effect.
Stimulants and blood-pressure medications: Additive stimulation or interference with blood-pressure control is plausible. Severity: caution; consequence: elevated blood pressure, agitation. Mitigating action: monitor blood pressure.
Populations who should avoid it: Pregnant or breastfeeding individuals; people with epilepsy or a seizure disorder; those with uncontrolled hypertension (e.g., resting blood pressure persistently ≥160/100 mmHg); people with severe agitation, mania, or bipolar disorder; and anyone with known DMAE sensitivity. Its unapproved regulatory status in the US means it should not be used as a substitute for evaluated medical care.

Risk Mitigation Strategies

Low starting dose with slow titration: Protocols typically begin at 250 mg once daily and increase gradually only if well tolerated, up to a typical ceiling around 1,000 mg/day, reducing the risk of overstimulation, headache, and agitation.
Dose early in the day: Taking the last dose before mid-afternoon prevents the insomnia and restlessness driven by the compound’s stimulating action.
Pair with adequate choline and take with food: Ensuring sufficient dietary or supplemental choline addresses cholinergic-demand headaches, and taking doses with food mitigates nausea and stomach upset.
Blood-pressure awareness: Resting blood pressure is monitored periodically, especially in older adults or those on blood-pressure medication, to catch stimulation-related elevations early.
Avoid stacking multiple cholinergics at once: Adding only one cholinergic agent at a time prevents cumulative cholinergic excess (jaw tension, salivation, muscle effects).
Verify product quality: Because a US analysis found frequent mislabeling, products with a batch certificate of analysis are preferable, avoiding unknowingly taking far more or less than intended and reducing dose-related side effects.

Therapeutic Protocol

Standard dose range: Leading practitioners and the nootropic literature describe 250–500 mg one to three times daily; older clinical studies in dementia used higher totals (up to roughly 1,000–2,000 mg/day). For general brain-health use, 250–1,000 mg/day is typical.
Conventional versus longevity-oriented approaches: A conventional clinical approach used higher short courses for age-related cognitive impairment, while the longevity/nootropic approach favors lower ongoing doses for maintenance and periodic higher “clearance” courses aimed at lipofuscin reduction; neither is framed here as the default.
Who popularized each approach: The higher-dose clinical use derives from mid-20th-century European practice around Lucidril; the lower-dose maintenance and age-pigment rationale traces to gerontology researchers Imre Zs-Nagy and Kalidas Nandy.
Best time of day: Morning and early afternoon, because of the compound’s stimulating, sleep-disrupting potential.
Half-life and dosing implication: Because the parent ester is hydrolyzed rapidly and the active DMAE clears over hours, effects are relatively short-lived, supporting split dosing across the day rather than a single dose.
Single versus split dosing: For daily totals above 250–500 mg, splitting into two or three doses (e.g., morning and midday) is generally preferred to maintain effect and limit peak-related side effects.
Genetic considerations: No validated pharmacogenetic guidance exists; variants in choline/acetylcholine handling could in principle influence dose needs but are not used clinically.
Sex-based considerations: No established sex-based dosing differences in humans; animal data hinting at a stronger female response are not a basis for dose adjustment.
Age-related considerations: Start lower and titrate more cautiously in older adults, who are more sensitive to cholinergic and stimulatory effects and more likely to be on interacting drugs.
Baseline biomarker considerations: Baseline blood pressure and, given hepatic handling, liver status are reasonable to know before starting, particularly in older users.
Pre-existing condition considerations: Response and tolerability differ by condition; those with cognitive impairment may perceive more benefit, while those with anxiety or hypertension may need more conservative dosing.

Discontinuation & Cycling

Lifelong versus short-term: Centrophenoxine is not established as a lifelong therapy; it is typically used in defined courses or as ongoing low-dose maintenance rather than as a permanent medication.
Withdrawal effects: No characteristic withdrawal syndrome has been documented; on stopping, any cognitive or energy benefit is expected to fade back toward baseline rather than to cause rebound symptoms.
Tapering: Formal tapering is generally unnecessary given the absence of a withdrawal syndrome, though reducing gradually from higher doses is reasonable.
Cycling: Many users cycle the compound (for example, several weeks on followed by a break, or intermittent higher-dose “clearance” courses) to limit tolerance and out of caution about continuous exposure to the DMAE component; there is no controlled evidence establishing an optimal cycle.

Sourcing and Quality

Regulatory and product landscape: In the US, centrophenoxine is an unapproved drug sold—often improperly labeled as a “dietary supplement”—as bulk powder or capsules; in some countries it is a prescription medicine (Lucidril). This shapes every sourcing decision.
What to look for: Vendors that provide a recent third-party certificate of analysis confirming both identity and quantity are preferable, because a published US analysis found that only 1 of 7 products contained the labeled amount within ±10%, with actual daily exposures ranging widely.
Formulation considerations: The hydrochloride salt (meclofenoxate hydrochloride) is the common form; capsules with verified content are preferable to unmeasured bulk powder for dose accuracy.
Reputable sources: Where it is a regulated medicine, a licensed pharmacy dispensing Lucidril offers the most reliable quality; in supplement markets, only vendors publishing independent batch testing should be considered.

Practical Considerations

Time to effect: Subtle alertness effects may be noticed within hours to days, whereas the age-pigment and cognitive effects studied in animals and older trials were assessed over weeks to months (roughly 8–12 weeks).
Common pitfalls: Dosing too high or too late in the day (causing insomnia and agitation), neglecting choline intake (causing headache), and buying unverified products (causing unpredictable dosing) are the most frequent mistakes.
Regulatory status: Not approved by the US Food and Drug Administration for any use and not lawfully a dietary supplement ingredient there; a prescription medicine in parts of Europe, Japan, and China. Any use in the US is off-label/gray-market.
Cost and accessibility: It is relatively inexpensive and widely available online, so cost is rarely limiting; the main accessibility issue is quality assurance rather than price.

Interaction with Foundational Habits

Sleep: Direct, potentially disruptive. Its stimulating cholinergic action can impair sleep onset if taken late; practical step is to keep all dosing to morning and early afternoon.
Nutrition: Direct and potentiating. Because the compound increases demand for choline to make acetylcholine, adequate dietary choline (eggs, liver, fish) or a choline supplement can improve tolerability and may enhance effect; taking with food also reduces stomach upset.
Exercise: Indirect, likely neutral to mildly supportive. There is no evidence it blunts training adaptations; any benefit is indirect through alertness. No specific timing around workouts is established.
Stress management: Indirect and variable. In sensitive or anxious individuals the stimulating action may worsen agitation and the stress response, so those prone to anxiety should use lower doses and monitor how it affects calmness.

Monitoring Protocol & Defining Success

Because centrophenoxine is not a formally monitored medicine, monitoring is pragmatic: establish a baseline, then track tolerability, blood pressure, and—given hepatic metabolism—liver markers in longer-term or higher-dose users.

Baseline testing before starting should include resting blood pressure and, for those planning ongoing use, a basic liver panel and a subjective cognition/energy/sleep baseline, so that changes can be interpreted against a known starting point.

Ongoing monitoring cadence: recheck blood pressure at about 2–4 weeks after starting or after a dose increase, and review liver markers and overall tolerability at roughly every 6–12 months of continued use.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Resting blood pressure	~110–125 / 70–80 mmHg	Detects stimulation-related elevation	mmHg = millimeters of mercury; measure seated after 5 min rest; conventional “normal” is <120/80
ALT	~10–26 U/L	Screens liver stress from chronic use	ALT = alanine aminotransferase, a liver enzyme; conventional labs allow up to ~40 U/L, higher than the tighter functional target
AST	~10–26 U/L	Complements ALT for liver health	AST = aspartate aminotransferase, a liver/muscle enzyme; best paired with ALT; recent intense exercise can raise it
GGT	<20 U/L (men), <15 U/L (women)	Sensitive marker of liver and oxidative stress	GGT = gamma-glutamyl transferase; conventional upper limits are higher (~50–60 U/L); fasting sample preferred
Heart rate	~55–75 bpm resting	Flags overstimulation	bpm = beats per minute; measure at rest, same time of day

Qualitative markers to track:

Sleep quality and time to fall asleep (early warning of overstimulation)
Subjective memory, focus, and mental clarity
Energy and mood, including any irritability or agitation
Presence of headache, jaw tension, or nausea

Emerging Research

Research framed for readers interested in whether centrophenoxine’s long-standing claims will be confirmed or overturned.

Human trial in hepatic encephalopathy: A randomized study combining meclofenoxate (500 mg once daily) with coenzyme Q10 in patients with liver cirrhosis and hepatic encephalopathy (confusion from liver failure) aimed to enroll 300 participants, with episode frequency and serum ammonia as endpoints (NCT03961087); its status is listed as unknown, underscoring how few active human trials exist.
Brain-aging gene expression: A 2022 study of near-lifelong meclofenoxate treatment in the short-lived killifish found it partly compensated for the age-related decline in neuron-activity genes but did not reverse aging-associated inflammatory gene expression (Bakhtogarimov et al., 2022), a result that both supports and tempers the longevity narrative.
Parkinson’s-related mechanism: A 2023 laboratory study showed meclofenoxate reduces aggregation of alpha-synuclein in vitro (Parui et al., 2023), offering a mechanistic lead for possible neuroprotection that could strengthen the case if confirmed in living systems.
Future direction — confirmatory human longevity and cognition trials: The decisive open question is whether the robust animal lipofuscin and antioxidant findings translate to humans; no adequately powered modern trial has tested this, and the existing systematic reviews of cholinergic agents (Tammenmaa et al., 2004) show how easily the case weakens under rigorous evaluation.

Conclusion

Centrophenoxine is a decades-old compound, built from a choline-like molecule joined to a carrier that helps it reach the brain, that has been used medically for age-related memory problems and poor brain blood flow and is now sold mainly as a memory supplement. Its reputation rests largely on a consistent animal finding: treated animals accumulate less of the waste pigment that builds up inside aging brain cells, alongside antioxidant and membrane effects that offer a plausible cellular story for slowing aspects of aging.

The evidence, however, is uneven. The strongest results come from animals, while the human record is thin, dated, and mixed, and the few rigorous pooled analyses found no clear benefit. Reported downsides—trouble sleeping, headache, overstimulation, and stomach upset—are usually mild and reversible, but long-term safety in people has never been properly studied, and the compound is unapproved in the United States with frequently mislabeled products.

Much of the enthusiastic material comes from sellers and from a small number of long-time academic advocates, so claims warrant a careful eye. For a risk-aware reader, centrophenoxine sits in an area of real biological interest paired with genuinely uncertain human evidence, where what remains unknown is as important as what is claimed.

Top - Benefits - Risks - Protocol

Centrophenoxine for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Reduction of Neuronal Lipofuscin (Age Pigment)

Low 🟩

Cognitive Support in Age-Related Cognitive Decline ⚠️ Conflicted

Antioxidant and Membrane Protection

Neuroprotection in Cerebral Hypoperfusion

Speculative 🟨

Lifespan Extension

Neurodegenerative Disease Modification

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

Overstimulation and Insomnia

Headache

Low 🟥

Gastrointestinal Upset

Cholinergic Symptoms

Irritability, Agitation, and Blood Pressure Effects

Speculative 🟨

Reproductive and Developmental Risk

Long-Term Safety and pCPA Exposure Uncertainty

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion